{"analyses":[{"ciLowerLimit":"-2.28","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.31","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.5460","paramType":"Difference in LS Means","paramValue":"1.01","statisticalMethod":"cLDA model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-8.36","spread":"-8.36","upperLimit":"-3.58","value":"-5.97"},{"groupId":"OG001","lowerLimit":"-9.63","spread":"-9.63","upperLimit":"-4.33","value":"-6.98"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"386"},{"groupId":"OG001","value":"363"}],"units":"Participants"}],"description":"EORTC QLQ-C30 was a questionnaire which included 30 questions that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Endometrial cancer (EC) received lenvatinib 20 milligrams (mg) orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study","id":"OG000","title":"Lenvatinib 20 mg + Pembrolizumab 200 mg"},{"description":"Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.","id":"OG001","title":"Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Analysis population consisted of ITT population which included all randomized participants. Here \"overall number of participants analyzed\" signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12","title":"Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in All-comer Participants","type":"SECONDARY","unitOfMeasure":"Score on a scale"}